Business Wire · Apr 2026
Official launch of InSight Wireless Reader; highlights Wi‑Fi connectivity, four-hormone measurement, HSA/FSA eligibility, and Android support.
Enabling better self care with at-home hormone tracking.
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Inito is a privately held at-home diagnostics company focused first on fertility hormone tracking and now expanding into broader home-based hormone diagnostics. Its flagship product measures four hormones at home and uses software/AI to predict fertile days, confirm ovulation, and surface personalized cycle insights.
Primary product
At-home fertility monitor / hormone tracker (Inito Fertility Monitor / InSight Wireless Reader)
Founded
2015
Headquarters
Houston, Texas, United States
Team size
200-300
Industry
Wellness and Fitness Services
Sub-industry
Fertility tech / at-home hormone diagnostics
Offices
0 jobs at Inito
Check back later for new openings
Business model
Stage
Series B
Total raised
$45M
Latest round
Series B · Dec 2025
Latest amount
$29M
Dec 2025 · Bertelsmann India Investments
Nov 2023 · Fireside Ventures
Mar 2019 · Y Combinator
Jan 2016 · Mecheri Smart Capital
Dec 2014 · Mecheri Smart Capital
Leadership
Co-Founder & CEO
Co-Founder & CTO
VP, Head of Marketing
Finance Head
Head of Growth
Engineering Lead
Senior Staff Engineer (Head of Embedded Platforms)
Lead Research and Development Scientist
Investors
Public pages emphasize an interdisciplinary, high-ownership culture with open-door communication, collaboration across hardware/software/biotech, user feedback loops, and an explicit focus on work-life balance and wellness.
Compensation
No public salary bands or compensation ranges were found in the sources reviewed.
Pricing
Direct-to-consumer starter kit with recurring fertility strip refills/consumables.
Differentiators
Technology
Customers
Competitors
Estimated revenue
$1M-$10M
Business Wire · Apr 2026
Official launch of InSight Wireless Reader; highlights Wi‑Fi connectivity, four-hormone measurement, HSA/FSA eligibility, and Android support.
Femtech Insider · Apr 2026
Reports the new reader launch and explains the differentiators versus LH-only ovulation tests.
Inito blog · Dec 2025
Company press release announcing the Series B, total equity funding of $45M, and expansion into broader at-home diagnostics.
YourStory · Dec 2025
Summarizes the round, investors, and expansion plans into additional diagnostics beyond fertility.
TechCrunch · Dec 2025
Coverage of the Series B and Inito’s roadmap beyond fertility into broader hormone and at-home health testing.